Table 1.
Demographic, subgroup, and MSA characteristics of IIM patients.
| Level | ASS | CADM | DM | IMNM | JDM | PM | |
|---|---|---|---|---|---|---|---|
| Number | 25 | 22 | 87 | 2 | 1 | 7 | |
| Age (SD)) | 51.40 | 50.32 | 43.60 | 33.50 | 11.00 | 50.71 | |
| (9.74) | (13.14) | (12.98) | (7.78) | (NA) | (17.47) | ||
| Sex (%) | Female | 18(72.0) | 17 (77.3) | 59 (67.8) | 0 (0.0) | 1 (100.0) | 5 (71.4) |
| Male | 7 (28.0) | 5 (22.7) | 28 (32.2) | 2 (100.0) | 0 (0.0) | 2 (28.6) | |
| MSA (%) | EJ | 5 (20.0) | 2 ( 9.1) | 5 ( 5.7) | 0 (0.0) | 0 (0.0) | 1 (14.3) |
| HMGCR | 0 ( 0.0) | 0 ( 0.0) | 0 ( 0.0) | 0 (0.0) | 0 (0.0) | 1 (14.3) | |
| Jo-1 | 14(56.0) | 0 ( 0.0) | 1 ( 1.1) | 0 (0.0) | 0 ( 0.0) | 1 (14.3) | |
| MDA5 | 0 ( 0.0) | 13 (59.1) | 52 (59.8) | 1 ( 50.0) | 1 (100.0) | 0 ( 0.0) | |
| Mi-2 | 0 ( 0.0) | 1 ( 4.5) | 4 ( 4.6) | 0 (0.0) | 0 (0.0) | 0 ( 0.0) | |
| MSA- | 1 ( 4.0) | 4 (18.2) | 8 ( 9.2) | 1 ( 50.0) | 0 (0.0) | 3 (42.9) | |
| NXP2 | 0 ( 0.0) | 0 ( 0.0) | 5 ( 5.7) | 0 (0.0) | 0 (0.0) | 0 ( 0.0) | |
| PL7 | 5 (20.0) | 0 ( 0.0) | 4 ( 4.6) | 0 (0.0) | 0 (0.0) | 0 ( 0.0) | |
| SAE | 0 ( 0.0) | 0 ( 0.0) | 1 ( 1.1) | 0 (0.0) | 0 (0.0) | 0 ( 0.0) | |
| SRP | 0 ( 0.0) | 0 ( 0.0) | 0 ( 0.0) | 0 (0.0) | 0 ( 0.0) | 1 (14.3) | |
| TIFl | 0 ( 0.0) | 2 ( 9.1) | 7 ( 8.0) | 0 (0.0) | 0 (0.0) | 0 ( 0.0) | |
IIM, idiopathic inflammatory myopathies; ASS, anti-synthetase syndrome; CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; IMNM, immune- mediated necrotizing myopathy; JDM, juvenile dermatomyositis; PM, polymyositis; MSA, myositis-specific antibody; EJ, glycyl-tRNA synthetase; HMGCR, 3-hydroxy-3- methylglutaryl-coenzyme A reductase; Jo-1, histidyl-tRNA synthetase; MDAS, melanoma differentiation-associated gene 5; Mi-2, nucleosome remodeling deacetylase complex; MSA-, MSA negative; NXP2, nuclear matrix protein 2; PL7, threonyl-tRNA synthetase; SAE, small ubiquitin-like modifier activating enzyme; SRP, signal recognition particle; TIF1, transcriptional intermediary factor 1.